The U.S. Food and Drug presidency approved Mozobil (plerixafor), a drug that helps boost the number of blood stem cells for bone marrow transplantation in next with certain forms of blood cancer. Mozobil is intended to be used in unification with the growth factor granulocyte-colony stimulating factor (G-CSF), for regimen of adults with assorted myeloma or non-Hodgkin's lymphomas.

More: - Brought to my attention by